BCL2L1 and Familial prostate cancer: Our findings revealed that ABT-263 and ABT-737 have the potential to enhance the sensitivity of the partially DTX-insensitive PC3 prostate cancer cell line, and that this effect is largely due to Bcl-xL inhibition.